Investigation Report on China Parecoxib Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||334086|
|出版日期||內容資訊||英文 25 Pages
|中國的Parecoxib市場分析 Investigation Report on China Parecoxib Market, 2010-2019|
|出版日期: 2015年07月02日||內容資訊: 英文 25 Pages||
For a long time, opioid has been one of the main drugs for the treatment of moderate and severe pain following surgery. However, as people's knowledge deepens, more and more doctors and patients come to realize that opioid is not really safe. Relevant studies show that opioid alone doesn't work effectively on pain resulting from exercises and that is not conducive to postoperative exercise and recovery. Besides, the use of opioid after surgery can cause such side effects as nausea, vomiting, sedation and uroschesis which are dose-dependent.
Parecoxib is a kind of COX-2 inhibitor which compared with opioid, can effectively inhibit COX-2 expression and reduce the synthesis of prostaglandin in the central and peripheral nervous system, inhibit hyperalgesia and increase pain threshold. Parecoxib's analgesia has been confirmed in studies conducted by anesthesia department, department of orthopaedics, gynecology and general surgery department. And its combination of fast lasting pain relief and safety has made it a better choice for postoperational analgesia.
Parecoxib, the first COX-2 inhibitor which can be injected through vein and muscle, was developed by Pharmacia & Upjohn and approved to enter Europe under the trade name of Dynastat in early 2002. Currently, it has been marketed in over 10 countries in the world.
Parecoxib develops fast after entering China in 2008. According to CRI's market survey, its annual sales value rose from less than CNY 20 million in 2008 to over CNY 200 million in 2014 with CAGR during this period reaching 54.70%. Currently, parecoxib in the Chinese market is monopolized by Upjohn that brought in a sales value of CNY 204 million in 2014.
It is possible for local parecoxib to come into the market in the next few years. And the market size of parecoxib in China is expected to keep growing.